Skip to main content
. 2020 Oct 27;12(10):722–737. doi: 10.4254/wjh.v12.i10.722

Table 1.

Rare indications for combined liver-kidney transplantation

Disease
Indication(s) for CLKT
Monogenic diseases with primary hepatic expression without significant parenchymal damage
Atypical hemolytic-uremic syndrome Renal failure and alternative complement pathway activity
AIP Renal failure and recurrent medically non-responsive AIP attacks
Primary hyperoxaluria Renal failure and metabolic control of the disease
Homozygous protein C deficiency Renal failure and coagulation control
Hereditary complement C3 deficiency Renal failure and risk reduction of recurrent infections (?)
Monogenic diseases with primary hepatic expression with parenchymal damage
Alpha-1-antitrypsin deficiency Renal failure and liver failure (cirrhosis)
Glycogen storage disease Renal failure with hepatocellular adenomatosis/carcinoma and metabolic control of the disease
Monogenic diseases with hepatic and extrahepatic manifestation
Nephronophthisis associated with liver fibrosis Renal failure and liver failure (cirrhosis)
Lecithin cholesterol acyl transferase deficiency Renal failure and metabolic control of disease
Methylmalonic acidemia Renal failure and metabolic decompensation
Other
Antibody mediated rejection of the kidney Renal failure and in the presence of positive CDC cross-match (?)

CLKT: Combined liver and kidney transplantation; AIP: Acute intermittent porphyria; CDC: Complement-dependent cytotoxicity.